TEXT

Top Abstract Text References

Enteropathogenic Escherichia coli (EPEC) is an enteric pathogen colonizing the small intestine and colon of infants with persistent watery diarrhea (28). Shiga toxin-producing E. coli (STEC), also variously referred to as enterohemorrhagic E. coli and verocytotoxin-producing E. coli, is a large-bowel pathogen causing both outbreaks and sporadic cases of hemorrhagic colitis and hemolytic-uremic syndrome (28). Both EPEC and STEC induce biochemical and morphological changes in infected eukaryotic cells. The cytoskeletal effects resulting in the attaching and effacing (A/E) lesion are characterized by intimate adherence of bacteria to epithelial cells with localized destruction and vesiculation of brush-border microvilli and rearrangement beneath adherent organisms of host cell cytoskeletal proteins, including filamentous actin, -actinin, talin, ezrin, and myosin light chain (8).

Induction of A/E lesion formation by EPEC and STEC is associated with a number of nuclear signaling events (30), as well as inducing changes in the cytosol of the infected host cell, including increased levels of inositol-1,4,5-trisphosphate (5, 11), cytosolic free calcium, and protein phosphorylation (1). Multiple signal transduction pathways converge to induce rearrangements of the actin cytoskeleton. The aim of this study was to further delineate responses in the host cell cytosol to EPEC and STEC infection by using a series of highly specific inhibitors against signaling pathways mediated by the enzymes phosphoinositide-specific phospholipase C, phosphoinositide 3-kinase, 5-lipoxygenase, and cyclooxygenase.

EPEC strain E2348/69 (serotype O127:H6) was kindly provided by E. Boedeker (University of Maryland, Baltimore). STEC strain CL56 (O157:H7) was donated by M. Karmali (Hospital for Sick Children, Toronto, Ontario, Canada). UMD864, kindly supplied by J. B. Kaper (University of Maryland), is an espB deletion mutant of E2348/69. It was used as a negative control because of its inability to trigger host signal transduction events (15). Bacteria were grown for 3 h in static, nonaerated Penassay broth (Difco, Detroit, Mich.) at 37°C to provide a mid-logarithmic-phase-growth culture, since bacteria at this stage induce more rapid formation of A/E lesions than do organisms grown to stationary phase (29).

The human laryngeal epithelial cell line HEp-2 (American Type Culture Collection, Manassas, Va.) was cultured in minimal essential medium (Gibco Laboratories, Grand Island, N.Y.) supplemented with 15% heat-inactivated fetal calf serum (Cansera International, Inc., Rexdale, Ontario, Canada), 0.5% glutamine (Gibco), 0.1% sodium bicarbonate (Gibco), and 2% penicillin-streptomycin (Gibco) in 25-cm² tissue culture flasks (Corning Glass Works, Corning, N.Y.) at 37°C in 5% CO₂.

Localization of -actinin was detected in infected epithelial cells, as described previously (12). Briefly, HEp-2 cells were seeded onto two-well chamber slides (Nunc, Inc., Naperville, Ill.) and were cultured overnight to obtain a subconfluent growth. Before bacterial infection the tissue culture medium was replaced with medium without antibiotics. Monolayers were then infected with 10⁹ E. coli bacteria at a multiplicity of infection of 100:1 at 37°C in 5% CO₂. After 3 h, nonadherent organisms were removed by washing the tissue culture cells six times with sterile, phosphate-buffered saline at pH 7.4. The monolayers were then fixed in 100% cold methanol at room temperature for 10 min. After being washed three times with phosphate-buffered saline, fixed cells were incubated with a 1-in-100 dilution of murine monoclonal immunoglobulin G anti--actinin (Sigma, Oakville, Ontario, Canada) as primary antibody for 1 h at 37°C with gentle shaking. Rewashed monolayers were then incubated with a 1-in-100 dilution fluorescein isothiocyanate-conjugated rabbit anti-murine immunoglobulin G (Jackson ImmunoResearch Laboratories, Inc., West Grove, Pa.) as secondary antibody with protection from light for 1 h at 37°C with continuous gentle agitation. Slides were then mounted with SlowFade Antifade Kits (Molecular Probes, Eugene, Oreg.) and examined by alternating phase-contrast and fluorescence microscopy (Leitz Dialux 22; Leica Canada, Inc., Willowdale, Ontario, Canada). Phase-contrast microscopy was used to quantitate the number of adherent bacteria on 100 randomly selected HEp-2 cells. The number of A/E lesions, as measured by the number of foci of -actinin accumulation in the same epithelial cells, was determined by immunofluorescence microscopy by three independent observers.

Signal transduction inhibitors were purchased from Calbiochem (San Diego, Calif.). HEp-2 cells were preincubated with the phosphoinositide-specific phospholipase C inhibitor 1-octadecyl-2-methyl-rac-glycero-3-phosphocholine (ET-18-OCH₃) (26), wortmannin or 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002) as a phosphoinositide 3-kinase inhibitor (35, 36), the 5-lipoxygenase inhibitor nordihydroguaretic acid (NDGA) (21), or a cyclooxygenase-2 inhibitor, N-(2-cyclohexyloxy-4-nitrophenyl)-methanesulfonamide (NS-398) (7), for 30 min to 3 h, at dosages recommended in previous studies. After removal of the inhibitor, tissue culture cells were rinsed thoroughly with minimal essential medium prior to infection with 10⁹ bacteria for 3 h at 37°C. The inhibitory effects of cell-signaling inhibitors were determined by their ability to disrupt formation of A/E lesions, as indicated by the number of foci of -actinin accumulation in infected epithelial cells.

Synthesis of leukotriene B4 in HEp-2 cells with and without exposure to a lipoxygenase inhibitor was measured in both culture supernatants and cell sonicates by immunoassay, as described previously (2). Samples were stored at 70°C and were assayed at 2 weeks using a commercial enzyme immunoassay (Cayman Chemical Co., Ann Arbor, Mich.). Results are expressed as means ± standard deviation. Analysis of variance (ANOVA) was used to test differences between multiple groups.

ET-18-OCH₃ inhibits -actinin accumulation in EPEC- and STEC-infected cells. Treatment of cell monolayers with various concentrations of the phosphoinositide-specific phospholipase C inhibitor ET-18-OCH₃, along its ethanol vehicle, did not affect the ability of EPEC strain E2348/69, STEC strain CL56, or the signaling-deficient mutant UMD864 to adhere to HEp-2 monolayers. The number of adherent bacteria on epithelial cells remained comparable under each of the different treatment conditions (data not shown). Furthermore, microcolony formation and localized adherence of EPEC were still detectable (Fig. 1A). The morphology of the bacterial microcolonies was not altered. When HEp-2 cells were infected with E2348/69 for 3 h at 37°C, the accumulation of -actinin, demonstrated by bright foci of fluorescence, corresponded to sites of bacterial adhesion (Fig. 1B). However, when tissue culture cells were pretreated with 80 µM ET-18-OCH₃ before infection, -actinin accumulation was reduced (Fig. 1C and D). The vehicle alone did not affect the -actinin reorganization. Similar inhibitory effects, following preincubation of host cells with ET-18-OCH₃, were observed during infection with STEC O157:H7 strain CL56 (data not shown). No -actinin response was detected using UMD864 as a negative control (Fig. 1E and F). Table 1 summarizes the results of semiquantitation of the effects of the phosphoinositide-specific phospholipase C inhibitor ET-18-OCH₃ on -actinin accumulation in both EPEC- and STEC-infected cells. A dose-dependent inhibition on the formation of A/E lesions on infected epithelial cells induced by these pathogenic bacteria was demonstrated (ANOVA, P < 0.05).

View larger version (101K): [in this window] [in a new window]   FIG. 1.   Reduced A/E lesion formation with phospholipase C inhibitor ET-18-OCH3 (approximate magnification, ×1,250). (A) Phase-contrast micrograph demonstrating adherent EPEC strain E2348/69 (arrows) on HEp-2 monolayers after coincubation for 3 h at 37°C. (B) Corresponding fluorescence micrograph showing -actinin accumulation, demonstrated by bright foci of fluorescence (arrows), underneath adherent microcolonies of bacteria. (C) Phase-contrast micrograph showing adherent E2348/69 on ET-18-OCH3-pretreated epithelial cells (arrows). (D) -Actinin accumulation under adherent EPEC was not observed in the corresponding fluorescence micrograph. (E) Phase-contrast micrograph demonstrating UMD864 adherent to tissue culture cells. (F) A negative -actinin response was detected when HEp-2 cells were infected with a signaling-deficient mutant.

View this table: [in this window] [in a new window]   TABLE 1.   Semiquantitation of the effects of inhibitors on aggregates of -actinin accumulation in cells infected with EPEC and STEC strains

Wortmannin inhibits aggregation of -actinin in EPEC- and STEC-infected cells. Wortmannin suspended in distilled water had no effect on initial bacterial adherence to HEp-2 epithelial cells. In the absence of the phosphoinositide 3-kinase inhibitor, formation of A/E lesions demonstrated by -actinin accumulation was observed (Fig. 2A and B). By contrast, after wortmannin treatment, fewer and less intense foci of -actinin localization were detected in EPEC strain E2348/69-infected tissue culture cells (Fig. 2C and D). Preincubation of HEp-2 cells with wortmannin before infection with STEC strain CL56 resulted in a similar change in the -actinin response (data not shown). The presence of 10 nM wortmannin led to 45 and 40% reductions in -actinin accumulation beneath adherent E2348/69 and CL56, respectively (ANOVA, P < 0.05). A dose-dependent effect of wortmannin was not tested because of its nonspecific inhibitory effects at concentrations higher than those employed in this study (6). More prolonged incubation (6 h) resulted in toxicity to the host epithelial cells.

View larger version (73K): [in this window] [in a new window]   FIG. 2.   Reduced A/E lesion formation with phosphoinositide 3-kinase inhibitor wortmannin (10 nM) (approximate magnification, ×1,250). (A) EPEC strain E2348/69 showing initial adherence to tissue culture HEp-2 cells by phase-contrast microscopy (arrows). (B) Intense foci of fluorescence demonstrate reaggregation of -actinin (arrows) corresponding to areas of bacterial attachment. (C) Phase-contrast micrograph depicting adherent E2348/69 on wortmannin-pretreated HEp-2 cells (arrows). (D) Fewer foci of -actinin accumulation (arrows) under attaching bacteria were detected in the corresponding fluorescence micrograph.

LY294002 inhibits -actinin reorganization in EPEC- and STEC-infected epithelia. Bacterial adherence to tissue culture cells was not affected by pretreatment of the epithelial cells with the phosphoinositide 3-kinase inhibitor LY294002 carried in dimethyl sulfoxide (DMSO) as the vehicle. Infection of HEp-2 cells with STEC strain CL56 resulted in recruitment of -actinin protein at the site of bacterial attachment. In contrast, LY294002 inhibited -actinin accumulation in CL56-infected cells, whereas DMSO alone did not affect the -actinin response. Similar inhibitory effects on -actinin localization were detected during infection with EPEC strain E2348/69. The inhibitory effect of LY294002 on EPEC- and STEC-induced A/E lesions was dose dependent (Table 1).

NDGA inhibits -actinin rearrangement in EPEC- and STEC-infected cells. NDGA pretreatment of tissue culture cells did not reduce the ability of bacteria to adhere to HEp-2 monolayers (data not shown). STEC strain CL56 caused the formation of A/E lesions in the absence of the leukotriene inhibitor NDGA (Fig. 3A and B). By contrast, fewer adherent bacteria were accompanied by foci of -actinin accumulation when HEp-2 tissue culture cells were preincubated with the cell-signaling inhibitor (Fig. 3C and D). Similar inhibitory effects on -actinin rearrangement were observed during EPEC infection (Fig. 3E and F). As summarized in Table 1, NDGA inhibited the recruitment of -actinin in both EPEC- and STEC-infected HEp-2 cells in a dose-dependent pattern.

View larger version (106K): [in this window] [in a new window]   FIG. 3.   Reduced A/E lesion formation with 5-lipoxygenase inhibitor NDGA (approximate magnification, ×1,250). (A) Phase-contrast micrograph showing initial adherence of STEC O157:H7 strain CL56 to HEp-2 cells (arrows) following infection for 3 h at 37°C. (B) Bright foci of -actinin fluorescence were detected in infected HEp-2 cells in regions subjacent to areas of bacterial adhesion (arrows). (C) Phase-contrast micrograph shows that CL56 adhered to NDGA-pretreated epithelial cells. (D) A negative -actinin response was detected in the corresponding fluorescence micrograph. (E) Phase-contrast micrograph of EPEC strain E2348/69 (O127:H6) binding to epithelial cells in tissue culture. (F) Few well-defined foci of -actinin fluorescence in HEp-2 cells below adherent EPEC were observed.

View larger version (11K): [in this window] [in a new window]   FIG. 4.   Leukotriene B4 (LTB-4) production is enhanced in EPEC-infected cells and inhibited by lipoxygenase inhibitor NDGA. Lane 1, lysates of HEp-2 cells incubated with DMSO (1 µl/ml); lane 2, lysate derived from cells incubated for 1 h with NDGA (35 µM); lane 3, cell lysates following incubation with NDGA (75 µM) for 1 h; lane 4, lysates obtained from cells incubated with EPEC strain E2348/69 (108) for 3 h; lane 5, cell lysates from HEp-2 cells preincubated for 1 h with NDGA (35 µM) and then infected with EPEC; lane 6, lysates from cells preincubated with NDGA (75 µM) for 1 h and then infected with EPEC. Results are the mean values of four separate experiments each run in duplicate. ***, P < 0.01 (ANOVA).

NS-398 does not inhibit -actinin reorganization in EPEC- and STEC-infected HEp-2 monolayers. Pretreatment of tissue culture cells with NS-398 did not reduce initial bacterial attachment. The cyclooxygenase-2 inhibitor NS-398 did not affect the -actinin rearrangement during EPEC and STEC infection, even at concentrations of up to 50 µM, despite the 50% inhibitory concentration of NS-398 of 3.8 µM (7) (Table 1).